SAN FRANCISCO (Thomson Financial) - Xtent Inc. on Tuesday reported what it
called "positive" six-month follow-up data from a clinical trial assessing the
safety and efficacy of its Custom NX drug eluting stent system for the treatment
of patients with coronary artery disease.
The primary endpoint was major adverse cardiac events (MACE) at 30 days,
with secondary endpoints of MACE at six months, binary restenosis, late loss,
and stent thrombosis.
The Menlo Park, Calif.-based company said for the primary endpoint, MACE at
30 days, the rate was 2.2%, consisting of two in-hospital non Q-wave myocardial
infarctions. At six-month follow-up, the MACE rate for was 7.8%.
Shares of Xtent rose 3.4% to $4.
Gabriel Madway
gm
COPYRIGHT
Copyright Thomson Financial News Limited 2007. All rights reserved.
The copying, republication or redistribution of Thomson Financial News Content,
including by framing or similar means, is expressly prohibited without the prior
written consent of Thomson Financial News.
|